Devyser Diagnostics AB (publ) (STO: DVYSR)
Sweden flag Sweden · Delayed Price · Currency is SEK
124.50
-4.50 (-3.49%)
Dec 3, 2024, 5:29 PM CET

Devyser Diagnostics AB Company Description

Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia.

The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories.

Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up.

The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient.

Devyser Diagnostics AB (publ) was incorporated in 2004 and is headquartered in Hägersten, Sweden.

Devyser Diagnostics AB (publ)
Country Sweden
Founded 2004
Industry Diagnostics & Research
Sector Healthcare
Employees 118
CEO Fredrik Alpsten

Contact Details

Address:
InstrumentvAegen 19
Hägersten, 126 53
Sweden
Phone 46 8 56 21 58 50
Website devyser.com

Stock Details

Ticker Symbol DVYSR
Exchange Nasdaq Stockholm
Fiscal Year January - December
Reporting Currency SEK
ISIN Number SE0016588867
SIC Code 2835

Key Executives

Name Position
Fredrik Alpsten Chief Executive Officer
Sabina Berlin Chief Financial Officer
Michael Uhlin Ph.D. Chief Scientific Officer
Camilla Wiberg Chief Human Resource Officer
Theis Kipling Chief Commercial Officer
John Murad Vice President and GM of Devyser US